DaVita Inc. Raises Target Price to $224 From $218
DVA•Related News
Royalty Pharma Q2 GAAP net income attributable to company falls 44% to $18 million; non-GAAP adjusted EBITDA rises 16% to $736 million
RPRX•
CS Disco Q2 revenue beats estimates on product expansion
LAW•
Vishay Intertechnology Q2 Revenue USD 888.575 Million
VSH•
Waters Corp <WAT.N>: Stifel Raises Target Price to $420 From $380
WAT•
Extreme Networks Q4 revenue beats on increased AI platform demand
EXTR•